Juvenile Idiopathic Arthritis (JIA) - Epidemiology Forecast - 2036

Juvenile Idiopathic Arthritis (JIA) Insights and Trends

• According to DelveInsight's analysis, the total diagnosed prevalent cases of JIA were ~141,800 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• A concentration of JIA cases in pediatric and adolescent age groups points to cumulative disease burden and possible delays in recognition and referral. This underscores opportunities for earlier identification, timely risk stratification, and proactive management in younger children to reduce progression and long-term complications.
• In the United States and EU4 and the UK, the most frequently observed subtypes of JIA are polyarticular JIA (both RF-positive and RF-negative) and oligoarticular JIA, whereas in Japan, systemic JIA (including Still's disease) along with polyarticular JIA (RF-positive and RF-negative) are the predominant forms.
• The observed female predominance and earlier onset of JIA highlight the importance of sex-specific screening and early intervention strategies, particularly in recognizing susceptibility patterns and addressing disease at onset to prevent long-term complications.

Juvenile Idiopathic Arthritis (JIA) Epidemiology Forecast in the 7MM

• 2025 JIA Prevalent Cases: ~141,800
• JIA Growth Rate (2026-2036): 1.8% CAGR

DelveInsight's 'Juvenile Idiopathic Arthritis (JIA) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the JIA, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Juvenile Idiopathic Arthritis (JIA) Understanding and Diagnosis Algorithm

Juvenile Idiopathic Arthritis (JIA) Overview and Diagnosis

JIA is the most common chronic inflammatory arthritis in children, caused by immune-mediated synovial inflammation leading to persistent joint pain, swelling, stiffness, and potential cartilage or bone damage, with possible extra-articular complications such as uveitis and impaired growth if untreated. It includes multiple subtypes defined by arthritis lasting =6 weeks, oligoarticular, polyarticular (RF-positive/negative), enthesitis-related, psoriatic, systemic JIA, and undifferentiated arthritis, with disease severity and clinical course varying widely across patients.

Juvenile Idiopathic Arthritis (JIA) Diagnosis

Diagnosis of JIA is clinical and based on persistent arthritis for =6 weeks in children under 16, supported by laboratory tests and imaging while excluding other causes of pediatric arthritis. Evaluation typically includes complete blood count (CBC), ESR, and CRP to assess inflammation; antinuclear antibody (ANA) for oligoarticular disease and uveitis risk; RF and anti-CCP to identify RA-like polyarticular disease; and HLA-B27 for enthesitis-related arthritis. Imaging such as X-ray, ultrasound, and MRI helps detect synovitis, effusions, and early joint damage. JIA is further classified using ILAR criteria into subtypes including oligoarticular, polyarticular (RF-positive/negative), systemic, psoriatic, enthesitis-related, and undifferentiated arthritis.

Juvenile Idiopathic Arthritis (JIA) Epidemiology

Key Findings from JIA Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total diagnosed prevalent cases of JIA in the 7MM were approximately 141,800 in 2025.
• In 2025, among mutation-specific prevalent cases of JIA in the US, oligoarticular JIA is the most prevalent subtype (~33,000 cases), reflecting its strong links with HLA class II alleles and ANA positivity, followed by polyarticular JIA accounting for ~29,000.
• In EU4 and the UK, oligoarticular JIA represented the largest share of subtype-specific diagnosed prevalent JIA cases, accounting for approximately 12,670 cases.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of JIA, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Juvenile Idiopathic Arthritis (JIA) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of JIA? What will be the growth opportunities across the 7MM concerning the patient population with JIA?
• What is the historical and forecasted JIA patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.